The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MRES | -88.56% | -43.9% | -10.91% | -100% |
| S&P | +15.58% | +78.13% | +12.24% | +470% |
Institute of BioMedical Research Corp. engages in research and development, quality control and standardization of pharmaceuticals, cosmetics and food products. Its products include Aerosan, MicrobEX, Klenet microbicidal towels, OralNet and Oral Ocean Power mouthwash, Purilair, colloidal silver, electro medical devices, beauty devices, electrodes, and garment electrodes. It also offers quality control, regulatory, and health care services; environmental analyses; building decontamination; and environmental protection and management services. The company was founded on July 26, 1990 and is headquartered in Niksic, Montenegro.
No news articles found for Institute Of Biomedical Research.
| Q1 2025 | YOY Change | |
|---|---|---|
| Revenue | $19.26K | 26.2% |
| Gross Profit | $9.13K | 405.7% |
| Gross Margin | 47.40% | 35.6% |
| Market Cap | $20.15M | 0.0% |
| Market Cap / Employee | $2.88M | 0.0% |
| Employees | 7 | 0.0% |
| Net Income | -$300.28K | -118.8% |
| EBITDA | -$290.75K | 74.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q1 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.80K | -88.1% |
| Accounts Receivable | $36.27K | 1.0% |
| Inventory | 0 | -36.8% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -18.61% | -83.1% |
| Return On Invested Capital | 102.80% | 0.0% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$252.79K | -529.3% |
| Operating Free Cash Flow | -$252.79K | -529.3% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 18.56 | 13.20 | 11.60 | 40.00 | - |
| Price to Book | 222.22 | 17.14 | - | ||
| Price to Sales | 335.14 | 271.71 | 1042.59 | 407.22 | -16.59% |
| Price to Tangible Book Value | -15.98 | -9.88 | - | ||
| Enterprise Value to EBITDA | -13.58 | 327.79 | -76.12 | - | |
| Return on Equity | 195.2% | 290.6% | 191.6% | -61.2% | - |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
